News & Events


Society for Neuro-Oncology Meeting

infuseon therapeutics will be presenting at the Society for Neuro-Oncology Meeting 21st Annual Meeting & Education day November 17-20 in Scottsdale, AZ.

Read More

Partnerships in Drug Delivery

infuseon therapeutics will be presenting at Partnerships in Drug Delivery October 27-28 at the Fairmont Copley Plaza in Boston, MA.

Read More

Dr. Michael Vogelbaum Presenting at Neurotech Investing and Partnering Conference

Dr. Vogelbaum will be presenting on the panel Therapeutic and Gene Delivery in Neuroscience: Next generation strategies for crossing the blood brain barrier include devices, carrier technology and nanovesicle technology will be featured and discussed. Case studies in glioblastoma, Alzheimer's, Parkinson's and other areas will highlight the potential for new classes of treatments to be developed.

Learn More


First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1

4/13/2018 | Journal of Neurosurgery
Progress in management of high-grade gliomas (HGGs) has been hampered by poor access of potential therapeutics to the CNS. The Cleveland Multiport Catheter (CMC), which deploys 4 independent delivery microcatheters, was developed to be a reliable, high-volume delivery device for delivery of therapeutic agents to the brain and other solid organs. The authors undertook this first-in-human clinical trial effort to evaluate the delivery characteristics of the CMC in patients with HGGs.

Read More

Infuseon Therapeutics Earns FDA Clearance for Novel Central Nervous System Delivery Device

Cleveland, Ohio – Infuseon Therapeutics’ novel central nervous system deliver device has received FDA 510(k) clearance as a therapeutic delivery device.
Infuseon Therapeutics’ Cleveland Multiport CatheterTM (CMC), a multiport convection-enhanced delivery catheter, was designed by neurosurgeon Michael Vogelbaum, MD, PhD, from Cleveland Clinic’s Brain Tumor and NeuroOncology Center and Department of Neurosurgery, to effectively deliver therapeutics to patients at the site of their disease. FDA clearance was granted in March 2017.
“This clearance of the CMC is important to developers of drugs and biologics that are intended for direct delivery to the CNS, as they are looking to use an FDA-cleared catheter for their IND-based clinical trials,” said Dr. Vogelbaum, Professor of Neurosurgery at Cleveland Clinic Lerner College of Medicine and Associate Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center.
The CMC features four independent delivery microcatheters. While the device was approved for delivery of a chemotherapy to the ventricles of the brain, its more general reliability as a loco-regional delivery device is being validated in IND-based pilot clinical trials involving delivery of a chemotherapy along with an MRI visible tracer in patients with recurrent high grade gliomas.
Since the first patient was treated in December 2014, 12 patients with malignant glioma have completed treatment with the device under the trial’s investigational protocol. For these procedures, two CMC devices have been placed in each patient using conventional neurosurgical stereotactic techniques. A chemotherapy has been infused along with an MRI visible tracer into tumor and/or tumor-infiltrated brain tissue via the microcatheters for up to 96 hours. Intermittent MRI monitoring has shown that the infusions have produced widespread distribution of the infusate into tumor-infiltrated brain.
“The extent of brain tissue covered and the reliability of the technique in these patients to date have surpassed past experience with other CED devices,” said Dr. Vogelbaum. As an inventor of the multiport catheter, Dr. Vogelbaum is entitled to a portion of any commercialization revenues Cleveland Clinic receives from Infuseon.
Additional investigations are continuing to determine optimal parameters for use of the CMC in solid tumors and in tumor-infiltrated brain. Use for treatment of other conditions affecting the brain and CNS, and in solid organs outside of the CNS, is also being explored.
Infuseon is currently seeking strategic partners with proprietary agents that can be delivered through their proprietary delivery devices. The company will be attending the 2017 BIO International Convention in San Diego, California, June 20-22.
About Infuseon Therapeutics – Infuseon Therapeutics was founded in 2012 by Cleveland Clinic for the purpose of developing its unique therapeutic delivery devices.  The patented Cleveland Multiport CatheterTM (CMC) is the first to have entered human clinical trials. Infuseon has collaborated with Parker-Hannifin Corporation, a global leader in motion and control technologies to enhance the medical design, development, and manufacturing expertise of the company. To learn more visit
Media contact: Neema Mayhugh, PhD  216 312-9165

Read More

Infuseon Therapeutics, Inc. CMO Discusses Delivery of Therapeutics Directly to the Brain at NeuroTech Investing and Partnering Conference


Cleveland, Ohio- infuseon therapeutics, Inc., the company that enables therapeutic delivery to the brain, announces that Dr. Michael A. Vogelbaum, Chief Medical Officer and co-inventor of the Cleveland Multiport Catheter system, will be speaking at the NeuroTech Investing and Partnering Conference taking place in Boston on Thursday, April 7.

Dr. Vogelbaum, a brain surgeon at Cleveland Clinic, will be part of the “Therapeutic and Gene Delivery in Neuroscience” panel discussion. The panel will be focused on next generation strategies for bypassing the blood brain barrier, including devices, carrier and nanovesicle technologies. Case studies in glioblastoma, Alzheimer’s Disease, Parkinson’s Disease and other areas will highlight the potential for new classes of treatments to be developed.

“The unmet need and true therapeutic target in glioblastoma is the infiltrating tumor that extends beyond the enhancing tumor,” said Vogelbaum, the associate director of the Brain Tumor and Neuro-Oncology Center at Cleveland Clinic.

“The Cleveland Multiport Catheter is designed specifically to deliver therapeutics to regions of brain, not just a small, localized target, thus addressing the problem of accessing infiltrating tumor or other regional targets in the brain. Our first-in-human clinical trial uses a co-delivered contrast agent which has allowed us to objectively validate the delivery to a volume of brain,” said Vogelbaum.

“We are pleased to be advancing the delivery of therapeutics that would otherwise be prevented from reaching their targets in the brain by the blood brain barrier,” he added.


infuseon therapeutics Inc. enables therapeutic delivery to the brain via the patented Cleveland Multiport Catheter (CMC) system. The company mission is to accurately deliver therapeutics to the brain that otherwise would be prevented from reaching their target by the Blood Brain Barrier. Infuseon Therapeutics, Inc. was founded in 2012 as a spinout company from Cleveland Clinic. For more information about infuseon therapeutics, Inc., please visit

Note: The Cleveland Multiport Catheter is an investigational device and can be used only in the setting of an FDA-approved clinical trial. 

Read More

Cleveland Clinic developing catheter for delivery of chemotherapy directly into the brain

10/27/2015 | FierceDrugDelivery
Cleveland Clinic's investigational convection-enhanced catheter for the delivery of drugs directly into the brain showed promise in first-in-human clinical trials of brain cancer patients. 

Read More

Cleveland Clinic innovation summit to focus on new therapies, progress in finding cures for diseases

10/23/2015 | The Plain Dealer
In Boyden, Iowa, a farm town of about 800 people, Cleveland Clinic's annual innovation summit typically is about as relevant to daily life as a space shuttle launch.

But this year, one of the innovations on display – a new iPad app used to assess concussion symptoms – has made a big difference, giving the town's high school football team a better way to diagnosis and treat head injuries.

Read more

This year's Medical Innovation Summit will highlight neurosciences innovation

7/9/2015 | Fresh Water Cleveland
Thousands of researchers, investors, entrepreneurs and those who are simply curious will descend upon the Cleveland Convocation Center October 26-28 for Cleveland Clinic Innovations Medical Innovation Summit. This year’s theme, The Neurosciences: Memory. Mood. Movement, will cover all aspects of the human brain and how it functions and malfunctions.

Read more

Who we are

Founded in 2012, infuseon therapeutics, inc. enables reliable therapeutic delivery to the brain via the patented Cleveland Multiport Catheter™ (CMC) system.

Contact Us


infuseon therapeutics is currently seeking academic and clinical partners for studies using the Cleveland Multiport Catheter™. 

Industry Partners

infuseon therapeutics is currently seeking industry partners interested in establishing strategic partnerships to deploy their agents using the Cleveland Multiport Catheter™.  Interested parties should contact Neema Mayhugh, PhD at: